Pharma Focus Asia

Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent

Monday, July 12, 2021

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that it has entered into a strategic commercial partnership with Tencent, one of the world's largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.

"As part of our preparations to become a commercial organization, we are focused on establishing key partnerships and building an offering of innovative and comprehensive technology solutions to engage and connect patients, healthcare providers, payers and other key stakeholders across the industry," said Kerry Blanchard, MD, PhD, CEO of Everest Medicines. "This partnership with Tencent, a global technology powerhouse, is a critical part of our overall commercial strategy as it will enable us to leverage the power of digital transformation, technology and data to strengthen our market position and ensure patients and healthcare providers in Greater China have greater access to the information and medicines they need."

As part of this partnership, Everest Medicines will explore a number of capabilities and potential solutions with Tencent, including ways to engage patients and healthcare professionals in disease awareness, particularly in various cancers, kidney diseases and severe infectious diseases, which tend to disproportionately impact people in the Greater China region and have limited treatment options, resulting in significant unmet medical need. In addition, the Companies will consider options to build a one-stop patient management ecosystem that spans disease management, from diagnosis to treatment and outcomes, as well as look at ways to leverage artificial intelligence and business intelligence tools to better identify customer profiles and improve treatment adoption.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024